The CDC expands its recommendation on booster shots to all adults aged 18 and older amid Omicron variant concerns; a federal judge temporarily blocks COVID-19 vaccine mandates for health workers in 10 states; the Supreme Court will begin hearing arguments on Mississippi’s landmark abortion case tomorrow.
Amid concerns of the novel Omicron variant, the CDC has expanded its recommendation on COVID-19 booster shots for all adults aged 18 and older. Reported by The Associated Press, the new recommendation comes after the agency’s approval of boosters for all adults, despite only recommended them for people aged 50 and older or those in high-risk areas. Pfizer is also expected to request authorization of its booster shot for 16- and 17-year-olds this week. In a technical brief yesterday, the World Health Organization said the global risk from the Omicron variant was very high, based on early evidence, and warned of future surges in cases.
As reported by ABC News, COVID-19 vaccine mandates for health workers were temporarily blocked by a federal judge yesterday in 10 states that had challenged the law. Ruling that CMS had no clear authority from Congress to enact the mandate for participating providers in Medicare and Medicaid, the preliminary injunction applies to Alaska, Arkansas, Iowa, Kansas, Missouri, Nebraska, New Hampshire, North Dakota, South Dakota and Wyoming. In other news, the White House Office of Management and Budget announced yesterday that federal workers who do not comply with the Biden administration’s vaccine mandate, which took effect November 22, will not face suspension or disciplinary action until January.
Reported by CBS News, the Supreme Court will begin hearing arguments tomorrow on the controversial Mississippi law that bans abortions after 15 weeks of pregnancy. With a 6-to-3 conservative majority, the Supreme Court’s decision on the abortion case, Dobbs v Jackson Women’s Health Organization, will mark the first major challenge to abortion rights since the 1992’s Planned Parenthood v Casey, which ruled that states cannot ban abortions before viability. Pro-abortion rights advocates have warned that a decision upholding the Mississippi law could lead to further challenges to the landmark 1973 Roe v Wade decision that established a constitutional right to an abortion.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More